Latest Insurance Coverage News

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

EQT Holdings Limited reported a robust 60% increase in net profit after tax for FY25, completing a strategic transformation while navigating significant regulatory challenges. The company outlined a growth-focused strategy for FY26, emphasizing digital innovation and margin improvement.

Income Asset Management reports a 34% rise in Q1 FY2026 revenue despite uncovering a $3 million fraud involving a former employee, maintaining positive EBITDA and strong client engagement.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Camplify Holdings has expanded its partnership with the NSW Government to provide caravans for flood-impacted residents, supporting housing recovery in the Mid North Coast and Hunter regions.

Adrad Holdings reported solid FY25 results with revenue climbing 8.9% to $153.1 million, despite a slight dip in EBITDA due to cost pressures. The company boosted its dividend by 18%, reflecting confidence in future growth.